Opinion
Video
Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification
Author(s):
Key Takeaways
- mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably.
- Both conditions involve the presence of metastases and sensitivity to androgen deprivation therapy (ADT).
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.
Video Player is loading.
Video content above is prompted by the following:
How do you define mCSPC and mHSPC? How are they different? (Lowrance et al. AUA/SUO Guideline, 2023) (NCCN, Prostate Cancer, v4.2024)
Related Videos
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy
Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy
Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial
Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions
Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches
Emerging Trends and Rising Prevalence of mCSPC
Related Content
